Development PipelineSGN-35T

an investigational CD30-directed, next generation antibody-drug conjugate with novel tripeptide linker

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

  • Phase 1

  • Phase 2

  • Phase 3

Program Resources

High-level synopsis of SGN-35T and ongoing clinical trials

Detailed information about SGN-35T clinical trials